Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E

Ohmori, Koichi; Yamada, Haruo; Yasuda, Akio; Yamamoto, Akira; Matsuura, Naosuke; Kiniwa, Mamoru

doi:10.1016/s0014-2999(03)01793-x

Cited by 14 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3) which caused decreases in hepatic TG, and MTP inhibitors which caused increases [19][20][21]. This finding further suggests that the lipid-lowering effects of S-2E may be not involved with PPAR-· activation or MTP inhibition, supporting the suggestion in our previous study [10].…”

Section: Discussionsupporting

confidence: 88%

“…The rats were divided into 4 groups (normal group, control group, S-2E 10 mg/kg group, and bezafibrate 10 mg/kg). To assess the changes in efficacy during treatment, 150 Ìl of blood was sampled from the caudal vein with a capillary blood collection tube (Terumo, Tokyo, Japan) by veniceratin under diethyl ether anesthesia 2 and 4 weeks after the start of dosing, as shown in our previous study [10]. After dilution with 300 Ìl of physiological saline to recover blood effectively, diluted plasma was recovered.…”

Section: Evaluation Of Test Agents On Anti-hyperlipidemic Action In Fmentioning

confidence: 99%

“…We have described a novel anti-hyperlipidemic agent, (+)-(S)-p-[1-(p-tert-butylphenyl)-2 -oxo-4-pyrrolidinyl] methoxybenzoic acid (S-2E), that suppressed VLDL particle production through inhibition of biosynthesis of both sterols and fatty acids, resulting in the lowering of the blood total cholesterol (TC) and TG in Zucker fatty rats [10]. In addition, this agent showed anti-hyperlipidemic effects, lowering blood cholesterol and TG even in homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, a pathologic animal model of human hypercholesterolemia [11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of a Novel Anti-Hyperlipidemic Agent, S-2E, on Blood Lipid Levels in Rats with Fructose-Induced Hypertriglyceridemia

et al. 2004

Self Cite

View full text Add to dashboard Cite

Using rats with fructose-induced hypertriglyceridemia, an animal model of human hypertriglyceridemia, we investigated whether (+)-(S)-p-[1-(p-tert-butylphenyl)-2-oxo-4-pyrrolidinyl]-methoxybenzoic acid (S-2E), a novel anti-hyperlipidemic agent, reduced the elevated levels of triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C), and then whether it elevated HDL-C levels. At doses of 3–30 mg/kg, S-2E reduced elevated TG levels and non-HDL-C levels simultaneously in a dose-dependent manner after a week. Furthermore, S-2E treatment at 10 mg/kg for 4 weeks showed similar effects, while the elongation of intervals between feeding periods led to further increases in these levels. Interestingly, S-2E increased blood HDL-C levels after 4 weeks of treatment. It is therefore reasonable to assume that S-2E may be useful to improve dyslipidemia such as hypertriglyceridemia and low levels of HDL-C.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Evaluation Of Test Agents On Anti-hyperlipidemic Action In Fmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of a Novel Anti-Hyperlipidemic Agent, S-2E, on Blood Lipid Levels in Rats with Fructose-Induced Hypertriglyceridemia

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

“…We focused on HMGCoA reductase for two reasons. First, reductase activity is directly inhibited by CoA thioesters (40,56,57); second, the hypolipidemic compound S-2E is converted to a CoA derivative and S-2E-CoA directly inhibits HMG-CoA reductase in a cell-free assay (58). However, we found that ESP 55016-CoA did not inhibit reductase in a cell-free assay under a variety of conditions.…”

Section: Discussionmentioning

confidence: 62%

Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

Cramer¹,

Goetz²,

Hopson

et al. 2004

Journal of Lipid Research

View full text Add to dashboard Cite

We have identified a novel -hydroxy-alkanedicarboxylic acid, ESP 55016, that favorably alters serum lipid variables in obese female Zucker (fa/fa) rats. ESP 55016 reduced serum non-HDL-cholesterol (non-HDL-C), triglyceride, and nonesterified fatty acid levels while increasing serum HDL-C and ␤ -hydroxybutyrate levels in a dose-dependent manner. ESP 55016 reduced fasting serum insulin and glucose levels while also suppressing weight gain. In primary rat hepatocytes, ESP 55016 increased the oxidation of

show abstract

“…Furthermore, S-2E lowered the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats. It was reported that S-2E may be useful in the treatment of familial hypercholesterolemia and mixed hyperlipidemia [31].…”

Section: Literature Reviewmentioning

confidence: 99%

A Review of antihyperlipidemic effect of synthetic phenolic compounds

Nawaz¹,

Shareef²,

Shahid³

et al. 2017

Matrix sci. medica

View full text Add to dashboard Cite

It is seen that most of the deaths are occurring due to diseases of cardiovascular system. There is a significant impact of lifestyle changes on the quality of health. Utilization of food highly rich with saturated fat and having low fiber content is one of the factors of disarray in energy balance. It is now evinced that hyperlipidemia is depicted as a major risk factor for the premature development of atherosclerosis and its cardiovascular complications. The prevalence of obesity has doubled in the past 25 years; today, two-thirds of adults are overweight in the United State [1].

show abstract

Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E

Cited by 14 publications

References 27 publications

Effects of a Novel Anti-Hyperlipidemic Agent, S-2E, on Blood Lipid Levels in Rats with Fructose-Induced Hypertriglyceridemia

Effects of a Novel Anti-Hyperlipidemic Agent, S-2E, on Blood Lipid Levels in Rats with Fructose-Induced Hypertriglyceridemia

Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

A Review of antihyperlipidemic effect of synthetic phenolic compounds

Contact Info

Product

Resources

About